The presence of somatic BRAF V600 mutations, for instance, is a clinically significant predictive biomarker for response to small‐molecule inhibitors of BRAF in patients with metastatic melanoma (Chapman et al., 2011; Hauschild et al., 2012). The gene discussed is BRAF; the disease is metastatic melanoma.